Since the outbreak of the COVID-19 pandemic in 2020, the biopharmaceutical industry has encountered numerous challenges, marking one of the most turbulent periods in its history. The emergence and global spread of the COVID-19 pandemic have accelerated innovation and research processes within the biopharmaceutical sector.

       Innovation is the primary driving force for development. This statement holds true regardless of the field. In the medical domain, imaging serves as a vital diagnostic and monitoring tool. By employing various imaging techniques such as X-rays, CT scans, MRI, among others, physicians can acquire detailed information about the internal structures and abnormalities of patients.